50. Dermatomyositis Clinical trials / Disease details


Clinical trials : 182 Drugs : 229 - (DrugBank : 88) / Drug target genes : 48 - Drug target pathways : 147

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-194822
27/8/201925/06/2019A Study of Ustekinumab in Participants with Active Polymyositis and Dermatomyositis who Have not Adequately Responded to one or More Standard-of-care TreatmentsA Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments PolymyositisDermatomyositisIntervention name : Ustekinumab
INN of the intervention : Ustekinumab
Dosage And administration of the intervention : Group 1: Ustekinumab + Placebo Group 2: Placebo + Ustekinumab Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
Control intervention name : placebo IV
INN of the control intervention : -
Dosage And administration of the control intervention : Group 1: Ustekinumab + Placebo Group 2: Placebo + Ustekinumab Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
Control intervention name : Placebo SC
INN of the control intervention : -
Dosage And administration of the control intervention : Group 2: Placebo + Ustekinumab Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
Janssen Pharmaceutical K.K.NULLrecruiting1875BOTH50Phase 3Japan
2NCT03981744
(ClinicalTrials.gov)
July 26, 20197/6/2019A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care TreatmentsA Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care TreatmentsPolymyositis;DermatomyositisDrug: Ustekinumab 6 mg/kg;Drug: Ustekinumab 90 mg;Drug: Placebo IV;Drug: Placebo SCJanssen Pharmaceutical K.K.NULLActive, not recruiting18 Years75 YearsAll51Phase 3Japan